Akamis Bio is an oncolytic virus drug development company whose proprietary T-SIGn virus platform enables intravenous delivery of payload carrying oncolytic viruses.
Iconic Therapeutics targets Tissue Factor (TF) in angiogenesis, inflammation, cell growth and metastasis to treat ophthalmologic, oncologic, and autoimmune diseases.
Curzion was developing a compound for Diffuse cutaneous systemic sclerosis (dcSSc), a rare, chronic autoimmune disease marked by fibrosis, or skin thickening, in areas including hands, forearms, upper arms and thighs.
Reneo Pharmaceuticals is a pharmaceutical company that specializes in discovering and developing therapies for rare and potentially life-threatening genetic mitochondrial diseases including Primary Mitochondrial Myopathies (PMMs), Fatty Acid Oxidation Disorders (FAODs) and McArdle disease.
Syntaxin developed bacterial-based protein therapeutics that inhibit cell secretion for the treatment of neurological, inflammatory and endocrine diseases.
